Watson (WPI) Launches Generic Version of Abbott's PROMETRIUM
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Join SI Premium – FREE
Watson Pharmaceuticals, Inc. (NYSE: WPI) confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They are also indicated for use in secondary amenorrhea.
Under the terms of the supply agreement, Abbott (NYSE: ABT) manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.
Under the terms of the supply agreement, Abbott (NYSE: ABT) manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Cleveland-Cliffs plans $1B upgrade at Middletown Works steel plant
- Sky Century Investment responds to OTC Markets stock promotion inquiry
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
